L-arginine-induced chronic pancreatitis in mice: Evaluating effects of pirfenidone and simvastatin

Table 1 Animal grouping and dosing schedule

Animal group	Treatment
I: Normal control group (n = 8)	Normal saline
II: Model control group (n = 10)	L-arginine administered: i.p. 4.50 g/kg, 2 doses at 1-hour intervals for week 1; i.p. 4.60 g/kg, 2 doses at 1-hour intervals for week 2; and i.p. 4.75 g/kg, 2 doses at 1-hour intervals for weeks 3 and 4
III: Pirfenidone-treated group (n = 10)	L-arginine administered: i.p. 4.50 g/kg, 2 doses at 1-hour intervals for week 1; i.p. 4.60 g/kg, 2 doses at 1-hour intervals for week 2; and i.p. 4.75 g/kg, 2 doses at 1-hour intervals for weeks 3 and 4. Pirfenidone administered: p.o. 400mg/kg, from week 3
IV: Simvastatin-treated group (n = 10)	L-arginine administered: i.p. 4.50 g/kg, 2 doses at 1-hour intervals for week 1; i.p. 4.60 g/kg, 2 doses at 1-hour intervals for week 2; and i.p. 4.75 g/kg, 2 doses at 1-hour intervals for weeks 3 and 4. Simvastatin administered: p.o. 1 mg/kg, for weeks 3-7
V: Pirfenidone + simvastatin-treated group (n = 10)	L-arginine administered: i.p. 4.50 g/kg, 2 doses at 1-hour intervals for week 1; i.p. 4.60 g/kg, 2 doses at 1-hour intervals for week 2; and i.p. 4.75 g/kg, 2 doses at 1-hour intervals for weeks 3 and 4. Pirfenidone administered: p.o. 400 mg/kg, for weeks 3-7; Simvastatin administered; p.o. 1mg/kg, for weeks 3-7
Total animals	48

i.p.: Intraperitoneal; p.o.: Per oral.